THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback